Literature DB >> 19842032

A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Matthew H Herynk1, Torsten Hopp, Yukun Cui, Airu Niu, Arnoldo Corona-Rodriguez, Suzanne A W Fuqua.   

Abstract

Estrogen receptor alpha (ERalpha) is highly regulated through multiple mechanisms including cell signaling, posttranslational modifications, and protein-protein interactions. We have previously identified a K303R ERalpha mutation within the hinge region of ERalpha. This mutation results in an altered posttranslational regulation and increased in vitro growth in the presence of low estrogen concentrations. We sought to determine if cells expressing this mutant ERalpha would display hypersensitive tumor growth in in vivo athymic ovariectomized nude mice. MCF-7 cells, stably expressing the K303R ERalpha, formed tumors in nude mice faster than cells expressing wild-type ERalpha in the presence of low levels of estrogen. When estrogen was withdrawn, all tumors regressed but half of the K303R ERalpha-expressing tumors became estrogen-independent and regrew. We evaluated potential mechanisms for the observed hypersensitivity. The mutant ERalpha did not demonstrate increased estrogen binding affinity, but did exhibit increased interactions with members of the SRC family of coactivators. The mutant ERalpha demonstrated increased levels and occupancy time on the pS2 promoter. In the presence of the K303R ERalpha, the SRC-3 and p300 coactivators also displayed increased levels and time on the pS2 promoter. The K303R ERalpha has, in part, lost critical negative regulation by the F domain. Collectively, these data demonstrate an important role for the K303R ERalpha mutation in hormonal regulation of tumor growth and estrogen-regulated promoter dynamics in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19842032      PMCID: PMC4151536          DOI: 10.1007/s10549-009-0580-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  37 in total

1.  Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.

Authors:  Matthew H Herynk; Amanda R Beyer; Yukun Cui; Heidi Weiss; Elizabeth Anderson; Tim P Green; Suzanne A W Fuqua
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

2.  Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity.

Authors:  Stephanie Sentis; Murielle Le Romancer; Claire Bianchin; Marie-Claude Rostan; Laura Corbo
Journal:  Mol Endocrinol       Date:  2005-06-16

3.  Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.

Authors:  K E Carlson; I Choi; A Gee; B S Katzenellenbogen; J A Katzenellenbogen
Journal:  Biochemistry       Date:  1997-12-02       Impact factor: 3.162

4.  Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.

Authors:  Yukun Cui; Airu Niu; Richard Pestell; Rakesh Kumar; Edward M Curran; Yunde Liu; Suzanne A W Fuqua
Journal:  Mol Endocrinol       Date:  2006-04-27

5.  Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.

Authors:  Mariam H Al-Dhaheri; Brian G Rowan
Journal:  Mol Endocrinol       Date:  2006-10-26

6.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities.

Authors:  X F Ding; C M Anderson; H Ma; H Hong; R M Uht; P J Kushner; M R Stallcup
Journal:  Mol Endocrinol       Date:  1998-02

7.  Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions.

Authors:  Akiko Koide; Changqing Zhao; Misuzu Naganuma; Judith Abrams; Sarah Deighton-Collins; Debra F Skafar; Shohei Koide
Journal:  Mol Endocrinol       Date:  2006-12-21

8.  P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation.

Authors:  Suresh K Rayala; Amjad H Talukder; Seetharaman Balasenthil; Robbin Tharakan; Christopher J Barnes; Rui-An Wang; C Marcelo Aldaz; Sohaib Khan; Rakesh Kumar
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

9.  Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity.

Authors:  Yukun Cui; Mao Zhang; Richard Pestell; Edward M Curran; Wade V Welshons; Suzanne A W Fuqua
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

10.  Understanding the human estrogen receptor-alpha using targeted mutagenesis.

Authors:  Debra F Skafar; Shohei Koide
Journal:  Mol Cell Endocrinol       Date:  2006-01-18       Impact factor: 4.102

View more
  7 in total

1.  Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.

Authors:  Ines Barone; Stefania Catalano; Luca Gelsomino; Stefania Marsico; Cinzia Giordano; Salvatore Panza; Daniela Bonofiglio; Gianluca Bossi; Kyle R Covington; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 2.  Estrogen receptor mutations and changes in downstream gene expression and signaling.

Authors:  Ines Barone; Lauren Brusco; Suzanne A W Fuqua
Journal:  Clin Cancer Res       Date:  2010-04-28       Impact factor: 12.531

3.  Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.

Authors:  Sakineh Abbasi; Mina Rasouli; Mehrnaz Nouri; Samira Kalbasi
Journal:  Int J Clin Exp Med       Date:  2012-11-18

Review 4.  Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.

Authors:  Suzanne A W Fuqua; Guowei Gu; Yassine Rechoum
Journal:  Breast Cancer Res Treat       Date:  2014-02-01       Impact factor: 4.872

Review 5.  The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.

Authors:  Sasha M Pejerrey; Derek Dustin; Jin-Ah Kim; Guowei Gu; Yassine Rechoum; Suzanne A W Fuqua
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

6.  A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.

Authors:  Nhan T Nguyen; Julie A Vendrell; Coralie Poulard; Balázs Győrffy; Sophie Goddard-Léon; Ivan Bièche; Laura Corbo; Muriel Le Romancer; Thomas Bachelot; Isabelle Treilleux; Pascale A Cohen
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

7.  Genome-wide Estrogen Receptor-α activation is sustained, not cyclical.

Authors:  Andrew N Holding; Amy E Cullen; Florian Markowetz
Journal:  Elife       Date:  2018-11-20       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.